6,090
Other income - 841
Total Revenue 1,530 20,793
EXPENSES:
Research and development, excluding
depreciation of $30,463 and
$20,493 included below 1,028,966 506,158
Depreciation and amortization 54,253 41,842
General and administrative 1,785,749 1,052,704
Total Expenses 2,868,968 1,600,704
LOSS FROM OPERATIONS (2,867,438) (1,579,911)
GAIN (LOSS) ON DERIVATIVE INSTRUMENTS 989,988 719,247
INTEREST INCOME 178,731 95,551
INTEREST EXPENSE (144,016) (347,246)
NET LOSS BEFORE INCOME TAXES (1,842,735) (1,112,359)
INCOME TAX PROVISION - -
NET LOSS (1,842,735) (1,112,359)
DIVIDENDS (424,815) -
NET LOSS $ (2,267,550) $(1,112,359)
NET LOSS PER COMMON SHARE (BASIC) $ (0.02) $ (0.01)
NET LOSS PER COMMON SHARE (DILUTED) $ (0.02) $ (0.01)
WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING, BASIC & DILUTED 115,708,186 82,928,432
'/>"/>SOURCE CEL-SCI Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
CEL-SCI Corporation Announces 2007 Financial Results2.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation3.
CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference4.
CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase5.
CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein6.
CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum7.
CEL-SCI Corporation Releases Letter to Shareholders8.
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug9.
NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 200810.
Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia11.
Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute